The Cytokine Basis of Cachexia and its Treatment: Are They Ready for Prime Time?

Journal of the American Medical Directors Association

Volumn 9, Issue 4, 2008, Pages 219-236

  Yeh, Shing Shing ^a   Blackwood, Kimathi ^b   Schuster, Michael W ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

anti cytokine medications; Cachexia; cytokines; pathophysiology

Indexed keywords

ACE 031; ACTIVIN RECEPTOR TYPE IIB AGONIST; ADALIMUMAB; AGENTS AFFECTING METABOLISM; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; ATLIZUMAB; CANNABINOID RECEPTOR AGONIST; CARNITINE; CREATINE; CYTOKINE; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ETANERCEPT; GAMMA INTERFERON; GLUTAMINE; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; MELANOCORTIN 4 RECEPTOR ANTAGONIST; METHOTREXATE; PENTOXIFYLLINE; PLACEBO; POLYUNSATURATED FATTY ACID; RETINOL; SCIO 469; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; UNINDEXED DRUG;

ANEMIA; ANOREXIA; BASAL CELL CARCINOMA; CACHEXIA; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; FOOD INTAKE; HEART FAILURE; HERPES ZOSTER; HUMAN; INFECTION; INTESTINE OBSTRUCTION; LIPID METABOLISM; LIPOLYSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE ATROPHY; MUSCLE METABOLISM; MYOPATHY; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; THROMBOCYTOPENIA; UVEITIS; WEIGHT REDUCTION;

EID: 42649113078     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2008.01.003     Document Type: Review

References (328)

1. F. Landi G. Zuccala G. Gambassi Body mass index and mortality among older people living in the community J Am Geriatr Soc 47 9 1999 1072 1076
2. M.E. Young Malnutrition and wound healing Heart Lung 17 1 1988 60 67
3. D.T. Dempsey J.L. Mullen G.P. Buzby The link between nutritional status and clinical outcome: can nutritional intervention modify it? American Journal of Clinical Nutrition 47 Suppl 2 1988 352 356
4. V.E. Baracos Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies Cancer 92 6 Suppl 2001 1669 1677
5. J.E. Morley D.R. Thomas M.M. Wilson Cachexia: pathophysiology and clinical relevance Am J Clin Nutr 83 4 2006 735 743
6. D.R. Thomas Distinguishing starvation from cachexia Clin Geriatr Med 18 4 2002 883 891
7. H.J. Cohen C.F. Pieper T. Harris K.M. Rao M.S. Currie The association of plasma IL-6 levels with functional disability in community-dwelling elderly J Gerontol 52 4 1997 M201 M208
8. E. Bruera ABC of palliative care Anorexia, cachexia, and nutrition Bmj 315 7117 1997 1219 1222
9. R.V. Milani M.R. Mehra S. Endres The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia Chest 110 4 1996 992 995
10. R. Ferrari The importance of cachexia in the syndrome of heart failure Eur Heart J 18 2 1997 187 189
11. R. Roubenoff R. Roubenoff J. Cannon Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation J Clin Invest 93 1994 2379 2386
12. M.I. Lewis Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 4 2002 434 436
13. D. Rigaud L.A. Angel M. Cerf Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption Am J Clin Nutr 60 5 1994 775 781
14. W.E. Mitch Getting beyond cross-sectional studies of abnormal nutritional indexes in dialysis patients Am J Clin Nutr 77 4 2003 760 761
15. W.E. Mitch Robert H Herman Memorial Award in Clinical Nutrition Lecture, 1997 Mechanisms causing loss of lean body mass in kidney disease Am J Clin Nutr 67 3 1998 359 366
16. L.C. Rall R. Roubenoff Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions Rheumatology (Oxford) 43 10 2004 1219 1223
17. S. Romagnani Regulation of the T cell response Clin Exp Allergy 36 11 2006 1357 1366
18. R.K. Chandra Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals Ageing Res Rev 3 1 2004 91 104
19. R. Roubenoff Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 6 3 2003 295 299
20. J. Norton J. Moley M. Green R. Carson S. Morrison Parabiotic transfer of cancer anorexia/cachexia in male rats Cancer Res 45 1985 5547 5552
21. U. Keller Pathophysiology of cancer cachexia Support Care Cancer 1 6 1993 290 294
22. P. Matthys A. Billiau Cytokines and cachexia Nutrition 13 9 1997 763 770
23. C.R. Plata-Salaman Cytokines and anorexia: a brief overview Semin Oncol 25 1 Suppl 1 1998 64 72
24. P.T. Todorov W.N. Field M.J. Tisdale Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361) Br J Cancer 80 11 1999 1734 1737
25. P.T. Todorov S.M. Wyke M.J. Tisdale Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle Cancer Res 67 23 2007 11419 11427
26. S.S. Yeh M.W. Schuster Geriatric cachexia: the role of cytokines Am J Clin Nutr 70 2 1999 183 197
27. B. Beutler TNF, immunity and inflammatory disease: lessons of the past decade J Investig Med 43 3 1995 227 235
28. B. Beutler TNF in pathophysiology: biosynthetic regulation J Invest Dermatol 95 6 Suppl 1990 81S 84S
29. B. Beutler A. Cerami The biology of cachectin/TNF–a primary mediator of the host response Annu Rev Immunol 7 1989 625 655
30. M. Calikoglu G. Sahin A. Unlu Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters Respiration 71 1 2004 45 50
31. M.B. Reid Y.P. Li Tumor necrosis factor-alpha and muscle wasting: a cellular perspective Respir Res 2 5 2001 269 272
32. M.J. Tisdale Loss of skeletal muscle in cancer: biochemical mechanisms Front Biosci 6 2001 D164 D174
33. C.H. Lang R.A. Frost Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection Curr Opin Clin Nutr Metab Care 5 3 2002 271 279
34. M.B. Reid Y.P. Li Cytokines and oxidative signalling in skeletal muscle Acta Physiol Scand 171 3 2001 225 232
35. B. Alvarez L.S. Quinn S. Busquets M.T. Quiles F.J. Lopez-Soriano J.M. Argiles Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells Biochim Biophys Acta 1542 1-3 2002 66 72
36. N. Carbo S. Busquets M. van Royen B. Alvarez F.J. Lopez-Soriano J.M. Argiles TNF-alpha is involved in activating DNA fragmentation in skeletal muscle Br J Cancer 86 6 2002 1012 1016
37. A. Greis J. Murgott S. Rafalzik R. Gerstberger T. Hubschle J. Roth Characterization of the febrile response induced by fibroblast-stimulating lipopeptide-1 in guinea pigs Am J Physiol Regul Integr Comp Physiol 293 1 2007 R152 R161
38. K. Kalantar-Zadeh J.D. Kopple M.H. Humphreys G. Block Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients Nephrol Dial Transplant 19 6 2004 1507 1519
39. D.C. Guttridge M.W. Mayo L.V. Madrid C.Y. Wang A.S. Baldwin Jr NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia Science 289 5488 2000 2363 2366
40. S. Acharyya K.J. Ladner L.L. Nelsen Cancer cachexia is regulated by selective targeting of skeletal muscle gene products J Clin Invest 114 3 2004 370 378
41. R.C. Langen A.M. Schols M.C. Kelders E.F. Wouters Y.M. Janssen-Heininger Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB Faseb J 15 7 2001 1169 1180
42. M. Figueras S. Busquets N. Carbo V. Almendro J.M. Argiles F.J. Lopez-Soriano Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue Int J Oncol 27 3 2005 855 860
43. R.C. Langen J.L. Van Der Velden A.M. Schols M.C. Kelders E.F. Wouters Y.M. Janssen-Heininger Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization Faseb J 18 2 2004 227 237
44. S. Akira IL-6-regulated transcription factors Int J Biochem Cell Biol 29 12 1997 1401 1418
45. S. Akira T. Taga T. Kishimoto Interleukin-6 in biology and medicine Adv Immunol 54 1993 1 78
46. S. Akira T. Kishimoto Role of interleukin-6 in macrophage function Curr Opin Hematol 3 1 1996 87 93
47. S.J. Hopkins Central nervous system recognition of peripheral inflammation: a neural, hormonal collaboration Acta Biomed 78 Suppl 1 2007 231 247
48. M. Trikha R. Corringham B. Klein J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 13 2003 4653 4665
49. A. Kaibara N.J. Espat T. Auffenberg Interleukin 6, but not ciliary neurotrophic factor or leukaemia inhibitory factor, is responsible for the acute phase response to turpentine-induced myositis Cytokine 10 6 1998 452 456
50. R. Shaoul A. Kessel E. Toubi A. Lanir O. Glazer M. Jaffe Leptin and cytokines levels in children with failure to thrive J Pediatr Gastroenterol Nutr 37 4 2003 487 491
51. J. Fujita T. Tsujinaka M. Yano Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways Int J Cancer 68 5 1996 637 643
52. S. Busquets C. Garcia-Martinez B. Alvarez N. Carbo F.J. Lopez-Soriano J.M. Argiles Calpain-3 gene expression is decreased during experimental cancer cachexia Biochim Biophys Acta 1475 1 2000 5 9
53. T. Tsujinaka J. Fujita C. Ebisui Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice J Clin Invest 97 1 1996 244 249
54. T.P. Hong N.A. Andersen K. Nielsen Interleukin-18 mRNA, but not interleukin-18 receptor mRNA, is constitutively expressed in islet beta-cells and up-regulated by interferon-gamma Eur Cytokine Netw 11 2 2000 193 205
55. C.A. Dinarello S. Endres S.N. Meydani M. Meydani M.K. Hellerstein Interleukin-1, anorexia, and dietary fatty acids Ann N Y Acad Sci 587 1990 332 338
56. C.A. Dinarello The IL-1 family and inflammatory diseases Clin Exp Rheumatol 20 5 Suppl 27 2002 S1 S13
57. C.A. Dinarello G. Fantuzzi Interleukin-18 and host defense against infection J Infect Dis 187 Suppl 2 2003 S370 S384
58. A.S. Fabricio G. Tringali G. Pozzoli Interleukin-1 mediates endothelin-1-induced fever and prostaglandin production in the preoptic area of rats Am J Physiol Regul Integr Comp Physiol 290 6 2006 R1515 R1523
59. A. Del Rey E. Roggero A. Randolf IL-1 resets glucose homeostasis at central levels Proc Natl Acad Sci U S A 103 43 2006 16039 16044
60. S. Ching H. Zhang N. Belevych Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration J Neurosci 27 39 2007 10476 10486
61. H.S. Oldenburg M.A. Rogy D.D. Lazarus Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6 Eur J Immunol 23 8 1993 1889 1894
62. N.P. Turrin S.E. Ilyin D.A. Gayle Interleukin-1beta system in anorectic catabolic tumor-bearing rats Curr Opin Clin Nutr Metab Care 7 4 2004 419 426
63. J. Francis P.S. MohanKumar S.M. MohanKumar S.K. Quadri Systemic administration of lipopolysaccharide increases plasma leptin levels: blockade by soluble interleukin-1 receptor Endocrine 10 3 1999 291 295
64. C.B. Lawrence N.J. Rothwell Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat J Neuroendocrinol 13 6 2001 490 495
65. J.M. Scarlett E.E. Jobst P.J. Enriori Regulation of central melanocortin signaling by interleukin-1 beta Endocrinology 148 9 2007 4217 4225
66. R. Blanque C. Meakin S. Millet C.R. Gardner Dual mechanisms of action of interferon-gamma in potentiating responses to LPS in mice: IL1, TNFalpha and IL6 production in serum and hypothermia Gen Pharmacol 32 4 1999 453 461
67. A.C. Louie J.G. Gallagher K. Sikora R. Levy S.A. Rosenberg T.C. Merigan Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma Blood 58 4 1981 712 718
68. P. Matthys R. Dijkmans P. Proost Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells Int J Cancer 49 1 1991 77 82
69. P. Matthys H. Heremans G. Opdenakker A. Billiau Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia Eur J Cancer 27 2 1991 182 187
70. B. Xu P.S. Kalra L.L. Moldawer S.P. Kalra Increased appetite augments hypothalamic NPY Y1 receptor gene expression: effects of anorexigenic ciliary neurotropic factor Regul Pept 75-76 1998 391 395
71. B. Xu M.G. Dube P.S. Kalra Anorectic effects of the cytokine, ciliary neurotropic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin Endocrinology 139 2 1998 466 473
72. P.S. Kalra M.G. Dube B. Xu W.G. Farmerie S.P. Kalra Neuropeptide Y (NPY) Y1 receptor mRNA is upregulated in association with transient hyperphagia and body weight gain: evidence for a hypothalamic site for concurrent development of leptin resistance J Neuroendocrinol 10 1 1998 43 49
73. S. Pu H. Dhillon L.L. Moldawer P.S. Kalra S.P. Kalra Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor J Neuroendocrinol 12 9 2000 827 832
74. G.R. Steinberg M.J. Watt B.C. Fam Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice Endocrinology 147 8 2006 3906 3914
75. G. Fantuzzi F. Benigni M. Sironi Ciliary neurotrophic factor (CNTF) induces serum amyloid A, hypoglycaemia and anorexia, and potentiates IL-1 induced corticosterone and IL-6 production in mice Cytokine 7 2 1995 150 156
76. M.J. Watt N. Dzamko W.G. Thomas CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK Nat Med 12 5 2006 541 548
77. Q.S. Liu M. Gao S.Y. Zhu The novel mechanism of recombinant human ciliary neurotrophic factor on the anti-diabetes activity Basic Clin Pharmacol Toxicol 101 2 2007 78 84
78. R.S. Ahima Overcoming insulin resistance with CNTF Nat Med 12 5 2006 511 512
79. D.J. Dyck Ciliary neural trophic factor: mimicking leptin's effects in skeletal muscle? Endocrinology 147 5 2006 2075 2076
80. M.W. Sleeman K. Garcia R. Liu Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice Proc Natl Acad Sci U S A 100 24 2003 14297 14302
81. M.C. Wang N.E. Forsberg Effects of ciliary neurotrophic factor (CNTF) on protein turnover in cultured muscle cells Cytokine 12 1 2000 41 48
82. D.H. Jho H.H. Engelhard R. Gandhi Ciliary neurotrophic factor upregulates ubiquitin-proteasome components in a rat model of neuronal injury Cytokine 27 6 2004 142 151
83. E.S. Akarsu I. Bishai F. Coceani Effect of ciliary neurotrophic factor on body temperature and cerebrospinal fluid prostanoids in the cat Brain Res Bull 45 1 1998 9 14
84. L. Shapiro X.X. Zhang R.G. Rupp S.M. Wolff C.A. Dinarello Ciliary neurotrophic factor is an endogenous pyrogen Proc Natl Acad Sci U S A 90 18 1993 8614 8618
85. J.H. Peters S.M. Simasko R.C. Ritter Leptin analog antagonizes leptin effects on food intake and body weight but mimics leptin-induced vagal afferent activation Endocrinology 148 6 2007 2878 2885
86. L.A. Velloso The hypothalamic control of feeding and thermogenesis: implications on the development of obesity [in Portuguese] Arq Bras Endocrinol Metabol 50 2 2006 165 176
87. B.E. Wisse K. Ogimoto G.J. Morton D.L. Williams M.W. Schwartz Central interleukin-1 (IL1) signaling is required for pharmacological, but not physiological, effects of leptin on energy balance Brain Res 1144 2007 101 106
88. P. Sarraf R.C. Frederich E.M. Turner Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia J Exp Med 185 1 1997 171 175
89. Y. Ogawa H. Masuzaki K. Hosoda Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin Diabetes 48 9 1999 1822 1829
90. J. Zhang M.K. Matheny N. Tumer M.K. Mitchell P.J. Scarpace Leptin antagonist reveals that the normalization of caloric intake and the thermic effect of food after high-fat feeding are leptin dependent Am J Physiol Regul Integr Comp Physiol 292 2 2007 R868 R874
91. M.W. Schwartz E. Peskind M. Raskind E.J. Boyko D. Porte Jr Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans Nat Med 2 5 1996 589 593
92. J.A. Levine N.L. Eberhardt M.D. Jensen Leptin responses to overfeeding: relationship with body fat and nonexercise activity thermogenesis J Clin Endocrinol Metab 84 8 1999 2751 2754
93. P.J. Havel Mechanisms regulating leptin production: implications for control of energy balance Am J Clin Nutr 70 3 1999 305 306
94. R. Somech S. Reif A. Golander Z. Spirer Leptin and C-reactive protein levels correlate during minor infection in children Isr Med Assoc J 9 2 2007 76 78
95. M. Lappas M. Permezel G.E. Rice Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2 Endocrinology 146 8 2005 3334 3342
96. K. Ohinata K. Suetsugu Y. Fujiwara M. Yoshikawa Activation of prostaglandin E receptor EP4 subtype suppresses food intake in mice Prostaglandins Other Lipid Mediat 81 1-2 2006 31 36
97. E.R. Busby G.A. Cooper T.P. Mommsen Novel role for prostaglandin E2 in fish hepatocytes: regulation of glucose metabolism J Endocrinol 174 1 2002 137 146
98. L. Elander L. Engstrom M. Hallbeck A. Blomqvist IL-1beta and LPS induce anorexia by distinct mechanisms differentially dependent on microsomal prostaglandin E synthase-1 Am J Physiol Regul Integr Comp Physiol 292 1 2007 R258 R267
99. V. Lehmmann B. Benninghoff W. Droge Tumor necrosis factor-induced activation of peritoneal macrophages is regulated by prostaglandin E2 and cAMP J Immunol 141 2 1988 587 591
100. S.M. Mahony M.J. Tisdale Role of prostaglandins in tumour necrosis factor induced weight loss Br J Cancer 60 1 1989 51 55
101. K.L. Smith M.J. Tisdale Mechanism of muscle protein degradation in cancer cachexia Br J Cancer 68 2 1993 314 318
102. M.P. Callery M.J. Mangino T. Kamei M.W. Flye Interleukin-6 production by endotoxin-stimulated Kupffer cells is regulated by prostaglandin E2 J Surg Res 48 6 1990 523 527
103. K. Lundholm J. Gelin A. Hyltander Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors Cancer Res 54 21 1994 5602 5606
104. J. Gelin C. Andersson K. Lundholm Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia Cancer Res 51 3 1991 880 885
105. V. Prima M. Tennant O.S. Gorbatyuk N. Muzyczka P.J. Scarpace S. Zolotukhin Differential modulation of energy balance by leptin, ciliary neurotrophic factor, and leukemia inhibitory factor gene delivery: microarray deoxyribonucleic acid-chip analysis of gene expression Endocrinology 145 4 2004 2035 2045
106. T. Naumann A. Steup O. Schnell Altered neuronal responses and regulation of neurotrophic proteins in the medial septum following fimbria-fornix transection in CNTF- and leukaemia inhibitory factor-deficient mice Eur J Neurosci 24 8 2006 2223 2232
107. M. Maccarrone T. Wenger Effects of cannabinoids on hypothalamic and reproductive function Handb Exp Pharmacol 168 2005 555 571
108. M.J. Lorite M.G. Thompson J.L. Drake G. Carling M.J. Tisdale Mechanism of muscle protein degradation induced by a cancer cachectic factor Br J Cancer 78 7 1998 850 856
109. M.J. Tisdale The ‘cancer cachectic factor’ Support Care Cancer 11 2 2003 73 78
110. S.M. Wyke M.J. Tisdale NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle Br J Cancer 92 4 2005 711 721
111. M.J. Lorite H.J. Smith J.A. Arnold A. Morris M.G. Thompson M.J. Tisdale Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF) Br J Cancer 85 2 2001 297 302
112. D. Cai J.D. Frantz N.E. Tawa Jr. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice Cell 119 2 2004 285 298
113. A.S. Whitehouse M.J. Tisdale Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB Br J Cancer 89 6 2003 1116 1122
114. M.J. Tisdale Cancer cachexia Langenbecks Arch Surg 389 4 2004 299 305
115. P.M. Sanders M.J. Tisdale Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage Br J Cancer 90 6 2004 1274 1278
116. S. Khan M.J. Tisdale Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor Int J Cancer 80 3 1999 444 447
117. S.T. Russell M.J. Tisdale Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo Br J Cancer 87 5 2002 580 584
118. E.J. Ramos S. Suzuki D. Marks A. Inui A. Asakawa M.M. Meguid Cancer anorexia-cachexia syndrome: cytokines and neuropeptides Curr Opin Clin Nutr Metab Care 7 4 2004 427 434
119. J.E. Morley D.R. Thomas Anorexia and aging: pathophysiology Nutrition 15 6 1999 499 503
120. S. Wong J. Pinkney Role of cytokines in regulating feeding behaviour Curr Drug Targets 5 3 2004 251 263
121. A.S. van Miert F. Kaya C.T. van Duin Changes in food intake and forestomach motility of dwarf goats by recombinant bovine cytokines (IL-1 beta, IL-2) and IFN-gamma Physiol Behav 52 5 1992 859 864
122. P. Montuschi G. Tringali D. Curro Evidence that interleukin-1 beta and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway Eur J Pharmacol 252 3 1994 253 260
123. P. Montuschi G. Tringali A. Mirtella L. Parente P. Preziosi P. Navarra Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro Eur J Pharmacol 275 1 1995 31 37
124. P. Montuschi G. Tringali L. Parente P. Preziosi P. Navarra Interleukin-1 beta- and tumour-necrosis-factor-induced inhibition of rat gastric fundus motility in vitro Pharmacol Res 30 1 1994 25 33
125. M.A. Plaza J. Fioramonti L. Bueno Role of central interleukin-1 beta in gastrointestinal motor disturbances induced by lipopolysaccharide in sheep Dig Dis Sci 42 2 1997 242 250
126. G. Suto A. Kiraly V. Plourde Y. Tache Intravenous interleukin-1-beta-induced inhibition of gastric emptying: involvement of central corticotrophin-releasing factor and prostaglandin pathways in rats Digestion 57 2 1996 135 140
127. G. Suto A. Kiraly Y. Tache Interleukin 1 beta inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor Gastroenterology 106 6 1994 1568 1575
128. G. Sonti S.E. Ilyin C.R. Plata-Salaman Anorexia induced by cytokine interactions at pathophysiological concentrations Am J Physiol 270 6 Pt 2 1996 R1394 R1402
129. G. Sonti S.E. Ilyin C.R. Plata-Salaman Neuropeptide Y blocks and reverses interleukin-1 beta-induced anorexia in rats Peptides 17 3 1996 517 520
130. C.R. Plata-Salaman Brain cytokine production and action in anorexia and cachexia Cytokine 15 1 2001 1 3
131. D.A. Papanicolaou G.P. Chrousos Interactions of the endocrine and immune systems in children and young adults Curr Opin Pediatr 7 4 1995 440 444
132. Z. Orban A.T. Remaley M. Sampson Z. Trajanoski G.P. Chrousos The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man J Clin Endocrinol Metab 84 6 1999 2126 2133
133. I.J. Elenkov D.G. Iezzoni A. Daly A.G. Harris G.P. Chrousos Cytokine dysregulation, inflammation and well-being Neuroimmunomodulation 12 5 2005 255 269
134. G. Mastorakos G.P. Chrousos J.S. Weber Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans J Clin Endocrinol Metab 77 6 1993 1690 1694
135. T. Inada N. Hamano M. Yamada A. Shirane K. Shingu Inducible nitric oxide synthase and tumor necrosis factor-alpha in delayed gastric emptying and gastrointestinal transit induced by lipopolysaccharide in mice Braz J Med Biol Res 39 11 2006 1425 1434
136. S.E. Kanoski E.K. Walls T.L. Davidson Interoceptive ”satiety” signals produced by leptin and CCK Peptides 28 5 2007 988 1002
137. J.R. Glowa P.W. Gold Corticotropin releasing hormone produces profound anorexigenic effects in the rhesus monkey Neuropeptides 18 1 1991 55 61
138. E.P. Zorrilla L.E. Reinhardt G.R. Valdez Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity J Pharmacol Exp Ther 310 3 2004 1027 1034
139. J.E. Morley Anorexia in older persons: epidemiology and optimal treatment Drugs Aging 8 2 1996 134 155
140. J.E. Morley E.N. Hernandez J.F. Flood Neuropeptide Y increases food intake in mice Am J Physiol 253 3 Pt 2 1987 R516 R522
141. J.E. Morley A.S. Levine M. Grace J. Kneip Peptide YY (PYY), a potent orexigenic agent Brain Res 341 1 1985 200 203
142. J.E. Morley A.S. Levine B.A. Gosnell J. Kneip M. Grace Effect of neuropeptide Y on ingestive behaviors in the rat Am J Physiol 252 3 Pt 2 1987 R599 R609
143. W.T. Chance A. Balasubramaniam J.E. Fischer Neuropeptide Y and the development of cancer anorexia Ann Surg 221 5 1995 579 587 discussion 87-9
144. W.T. Chance J.E. Fischer Neurotransmitters and food intake Nutrition 9 5 1993 470 471
145. W.T. Chance A. Balasubramaniam R. Dayal J. Brown J.E. Fischer Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats Life Sci 54 24 1994 1869 1874
146. B.G. Stanley W. Magdalin A. Seirafi M.M. Nguyen S.F. Leibowitz Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect Peptides 13 3 1992 581 587
147. S.F. Leibowitz Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism Trends Neurosci 15 12 1992 491 497
148. A. Inui M.M. Meguid Cachexia and obesity: two sides of one coin? Curr Opin Clin Nutr Metab Care 6 4 2003 395 399
149. A. Inui Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52 2 2002 72 91
150. J. Nandi M.M. Meguid A. Inui Central mechanisms involved with catabolism Curr Opin Clin Nutr Metab Care 5 4 2002 407 418
151. T.C. Kirkham C.A. Walsh J. Gibbs G.P. Smith J. Leban J. McDermed A novel bombesin receptor antagonist selectively blocks the satiety action of peripherally administered bombesin Pharmacol Biochem Behav 48 3 1994 809 811
152. T.C. Kirkham J. Gibbs G.P. Smith Satiating effect of bombesin is mediated by receptors perfused by celiac artery Am J Physiol 261 3 Pt 2 1991 R614 R618
153. J.F. Flood A.J. Silver J.E. Morley Do peptide-induced changes in feeding occur because of changes in motivation to eat? Peptides 11 2 1990 265 270
154. A.S. Levine J.E. Morley Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism Pharmacol Biochem Behav 16 6 1982 897 902
155. J.E. Morley J.F. Flood M. Horowitz P.M. Morley M.J. Walter Modulation of food intake by peripherally administered amylin Am J Physiol 267 1 Pt 2 1994 R178 R184
156. J. Le Sauter N. Geary Hepatic portal glucagon infusion decreases spontaneous meal size in rats Am J Physiol 261 1 Pt 2 1991 R154 R161
157. N. Geary J. Le Sauter U. Noh Glucagon acts in the liver to control spontaneous meal size in rats Am J Physiol 264 1 Pt 2 1993 R116 R122
158. G.P. Smith J. Gibbs Gut peptides and postprandial satiety Fed Proc 43 14 1984 2889 2892
159. T.H. Moran P.R. McHugh Cholecystokinin suppresses food intake by inhibiting gastric emptying Am J Physiol 242 5 1982 R491 R497
160. J.E. Morley A.S. Levine Involvement of dynorphin and the kappa opioid receptor in feeding Peptides 4 6 1983 797 800
161. L.Y. Kong M.K. McMillian P.M. Hudson L. Jin J.S. Hong Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures J Pharmacol Exp Ther 280 1 1997 61 66
162. C.C. Chao G. Gekker S. Hu W.S. Sheng P.S. Portoghese P.K. Peterson Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by dynorphin Biochem Pharmacol 50 5 1995 715 722
163. F.S. Gaskin S.A. Farr W.A. Banks V.B. Kumar J.E. Morley Ghrelin-induced feeding is dependent on nitric oxide Peptides 24 6 2003 913 918
164. R. Vozzo G.A. Wittert I.M. Chapman Evidence that nitric oxide stimulates feeding in the marsupial Sminthopsis crassicaudata Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 123 2 1999 145 151
165. J.E. Morley S.A. Farr M.D. Suarez J.F. Flood Nitric oxide synthase inhibition and food intake: effects on motivation to eat and in female mice Pharmacol Biochem Behav 50 3 1995 369 373
166. J.E. Morley J.F. Flood Evidence that nitric oxide modulates food intake in mice Life Sci 49 10 1991 707 711
167. W. Langhans Signals generating anorexia during acute illness Proc Nutr Soc 66 3 2007 321 330
168. M.D. DeBoer Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 10 4 2007 457 462
169. A. Uehara C. Sekiya Y. Takasugi M. Namiki A. Arimura Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor Am J Physiol 257 3 Pt 2 1989 R613 R617
170. J.M. Daun D.O. McCarthy The role of cholecystokinin in interleukin-1-induced anorexia Physiol Behav 54 2 1993 237 241
171. T. Bungo S.I. Kawakami A. Ohgushi Intracerebroventricular injection of fusaric acid attenuates the anorexia by glucagon-like peptide-1 in the neonatal chick Pharmacol Biochem Behav 70 2-3 2001 251 255
172. J.L. Lachey D.A. D'Alessio L. Rinaman J.K. Elmquist D.J. Drucker R.J. Seeley The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice Endocrinology 146 1 2005 458 462
173. T. Tachibana K. Hirofuji M. Matsumoto The hypothalamus is involved in the anorexic effect of glucagon-like peptide-1 in chicks Comp Biochem Physiol A Mol Integr Physiol 137 1 2004 183 188
174. N. Fujita H. Sakamaki S. Uotani Intracerebroventricular administration of insulin and glucose inhibits the anorectic action of leptin in rats Exp Biol Med (Maywood) 228 10 2003 1156 1161
175. T. Sato A. Laviano M.M. Meguid F. Rossi-Fanelli Plasma leptin, insulin and free tryptophan contribute to cytokine-induced anorexia Adv Exp Med Biol 527 2003 233 239
176. Y.W. Kim K.H. Kim D.K. Ahn Time-course changes of hormones and cytokines by lipopolysaccharide and its relation with anorexia J Physiol Sci 57 3 2007 159 165
177. A. Uehara Y. Ishikawa T. Okumura Indomethacin blocks the anorexic action of interleukin-1 Eur J Pharmacol 170 3 1989 257 260
178. A. Uehara T. Okumura C. Sekiya K. Okamura Y. Takasugi M. Namiki Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin Biochem Biophys Res Commun 162 3 1989 1578 1584
179. F. Shintani S. Kanba T. Nakaki Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus J Neurosci 13 8 1993 3574 3581
180. E.M. Somerville J.M. Horwood M.D. Lee G.A. Kennett P.G. Clifton 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice Eur J Neurosci 25 10 2007 3115 3124
181. L.K. Heisler M.A. Cowley T. Kishi Central serotonin and melanocortin pathways regulating energy homeostasis Ann N Y Acad Sci 994 2003 169 174
182. J.J. Hillebrand M.J. Kas R.A. Adan To eat or not to eat; regulation by the melanocortin system Physiol Behav 89 1 2006 97 102
183. C.C. Cheung D.K. Clifton R.A. Steiner Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus Endocrinology 138 10 1997 4489 4492
184. D.L. Marks R.D. Cone Central melanocortins and the regulation of weight during acute and chronic disease Recent Prog Horm Res 56 2001 359 375
185. A.P. Coll Effects of pro-opiomelanocortin (POMC) on food intake and body weight: mechanisms and therapeutic potential? Clin Sci (Lond) 113 4 2007 171 182
186. M. Katahira Y. Iwasaki Y. Aoki Y. Oiso H. Saito Cytokine regulation of the rat proopiomelanocortin gene expression in AtT-20 cells Endocrinology 139 5 1998 2414 2422
187. T.M. Mizuno C.V. Mobbs Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting Endocrinology 140 2 1999 814 817
188. W. Cheung P.X. Yu B.M. Little R.D. Cone D.L. Marks R.H. Mak Role of leptin and melanocortin signaling in uremia-associated cachexia J Clin Invest 115 6 2005 1659 1665
189. M.A. Cowley J.L. Smart M. Rubinstein Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus Nature 411 6836 2001 480 484
190. S. Pinto A.G. Roseberry H. Liu Rapid rewiring of arcuate nucleus feeding circuits by leptin Science 304 5667 2004 110 115
191. T.M. Mizuno S.P. Kleopoulos H.T. Bergen J.L. Roberts C.A. Priest C.V. Mobbs Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin Diabetes 47 2 1998 294 297
192. M.M. Hagan P.A. Rushing M.W. Schwartz Role of the CNS melanocortin system in the response to overfeeding J Neurosci 19 6 1999 2362 2367
193. M. Lopez R. Lage Y.C. Tung Orexin expression is regulated by alpha-melanocyte-stimulating hormone J Neuroendocrinol 19 9 2007 703 707
194. D.M. Jacobowitz T.L. O'Donohue alpha-Melanocyte stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain Proc Natl Acad Sci U S A 75 12 1978 6300 6304
195. D. Huszar C.A. Lynch V. Fairchild-Huntress Targeted disruption of the melanocortin-4 receptor results in obesity in mice Cell 88 1 1997 131 141
196. R.H. Mak W. Cheung R.D. Cone D.L. Marks Leptin and inflammation-associated cachexia in chronic kidney disease Kidney Int 69 5 2006 794 797
197. R.H. Mak W. Cheung Energy homeostasis and cachexia in chronic kidney disease Pediatr Nephrol 21 12 2006 1807 1814
198. W.W. Cheung H.J. Kuo S. Markison Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice J Am Soc Nephrol 18 9 2007 2517 2524
199. M. Diksic S.N. Young Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan J Neurochem 78 6 2001 1185 1200
200. A. Laviano A. Cascino M. Muscaritoli F. Rossi Fanelli Pathogenetic and therapeutic aspects of secondary anorexia [in Italian] Ann Ital Med Int 15 3 2000 199 205
201. T. Sato A. Laviano M.M. Meguid C. Chen F. Rossi-Fanelli K. Hatakeyama Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia Clin Nutr 22 2 2003 139 146
202. F. Rossi Fanelli C. Cangiano F. Ceci Plasma tryptophan and anorexia in human cancer Eur J Cancer Clin Oncol 22 1 1986 89 95
203. C. Cangiano A. Cascino F. Ceci Plasma and CSF tryptophan in cancer anorexia J Neural Transm Gen Sect 81 3 1990 225 233
204. C. Cangiano U. Testa M. Muscaritoli Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation Anticancer Res 14 3B 1994 1451 1455
205. A.J. Dunn Infection as a stressor: a cytokine-mediated activation of the hypothalamo-pituitary-adrenal axis? Ciba Found Symp 172 1993 226 239 discussion 39-42
206. R.C. Gaillard E. Spinedi T. Chautard F.P. Pralong Cytokines, leptin, and the hypothalamo-pituitary-adrenal axis Ann N Y Acad Sci 917 2000 647 657
207. A.H. Staurenghi R.G. Masera P. Prolo Hypothalamic-pituitary-adrenal axis function, psychopathological traits, and natural killer (NK) cell activity in anorexia nervosa Psychoneuroendocrinology 22 8 1997 575 590
208. J. Raber R.D. O'Shea F.E. Bloom I.L. Campbell Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice J Neurosci 17 24 1997 9473 9480
209. J.A. Palesty S.J. Dudrick What we have learned about cachexia in gastrointestinal cancer Dig Dis 21 3 2003 198 213
210. W.K. Evans R. Makuch G.H. Clamon Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer Cancer Res 45 7 1985 3347 3353
211. A. Gualco C. Opasich S. Brazzo Metabolic frailty in malnourished heart failure patients [in Italian] Monaldi Arch Chest Dis 68 2 2007 115 120
212. A. Laviano M.M. Meguid I. Preziosa F.R. Fanelli Oxidative stress and wasting in cancer Curr Opin Clin Nutr Metab Care 10 4 2007 449 456
213. L.A. Schaap S.M. Pluijm D.J. Deeg M. Visser Inflammatory markers and loss of muscle mass (sarcopenia) and strength Am J Med 119 6 2006 526 e9 526 e17
214. J.K. Riley K. Takeda S. Akira R.D. Schreiber Interleukin-10 receptor signaling through the JAK-STAT pathway Requirement for two distinct receptor-derived signals for anti-inflammatory action J Biol Chem 274 23 1999 16513 16521
215. I. de Blaauw N.E. Deutz M.F. von Meyenfeldt Cachexia in cancer: disturbances in the protein and aminoacid metabolism [in Dutch] Ned Tijdschr Geneeskd 143 27 1999 1408 1413
216. K.W. Hulsewe N.E. Deutz I. de Blaauw R.R. van der Hulst M.M. von Meyenfeldt P.B. Soeters Liver protein and glutamine metabolism during cachexia Proc Nutr Soc 56 2 1997 801 806
217. J.K. Shabert D.W. Wilmore Glutamine deficiency as a cause of human immunodeficiency virus wasting Med Hypotheses 46 3 1996 252 256
218. S. von Haehling W. Doehner S.D. Anker Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res 73 2 2007 298 309
219. E. Bonar A. Dubin A. Bierczynska-Krzysik Identification of major cellular proteins synthesized in response to interleukin-1 and interleukin-6 in human hepatoma HepG2 cells Cytokine 33 2 2006 111 117
220. C. Arnaud F. Burger S. Steffens Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins Arterioscler Thromb Vasc Biol 25 6 2005 1231 1236
221. D.L. Pouliquen Hepatic mitochondrial function and brain tumours Curr Opin Clin Nutr Metab Care 10 4 2007 475 479
222. D. Sanchis S. Busquets B. Alvarez D. Ricquier F.J. Lopez-Soriano J.M. Argiles Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model FEBS Lett 436 3 1998 415 418
223. S. Busquets V. Almendro E. Barreiro M. Figueras J.M. Argiles F.J. Lopez-Soriano Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake Involvement of ROS in a model of mouse cancer cachexia FEBS Lett 579 3 2005 717 722
224. J.M. Argiles S. Busquets F.J. Lopez-Soriano The role of uncoupling proteins in pathophysiological states Biochem Biophys Res Commun 293 4 2002 1145 1152
225. S. Busquets D. Sanchis B. Alvarez D. Ricquier F.J. Lopez-Soriano J.M. Argiles In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 440 3 1998 348 350
226. W.E. Mitch A.L. Goldberg Mechanisms of muscle wasting The role of the ubiquitin-proteasome pathway N Engl J Med 335 25 1996 1897 1905
227. Z.J. Chen Ubiquitin signalling in the NF-kappaB pathway Nat Cell Biol 7 8 2005 758 765
228. M. Bossola M. Muscaritoli P. Costelli Increased muscle proteasome activity correlates with disease severity in gastric cancer patients Ann Surg 237 3 2003 384 389
229. P. Costelli M. Bossola M. Muscaritoli Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats Cytokine 19 1 2002 1 5
230. M. Bossola M. Muscaritoli P. Costelli Increased muscle ubiquitin mRNA levels in gastric cancer patients Am J Physiol Regul Integr Comp Physiol 280 5 2001 R1518 R1523
231. S.M. Wyke S.T. Russell M.J. Tisdale Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation Br J Cancer 91 9 2004 1742 1750
232. K.C. Fearon The Sir David Cuthbertson Medal Lecture 1991 The mechanisms and treatment of weight loss in cancer Proc Nutr Soc 51 2 1992 251 265
233. W.C. Hulsmann M.L. Dubelaar Effects of tumor necrosis factor (TNF) on lipolytic activities of rat heart Mol Cell Biochem 79 2 1988 147 151
234. I. Hardardottir W. Doerrler K.R. Feingold C. Grunfeld Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism Biochem Biophys Res Commun 186 1 1992 237 243
235. M.K. Marshall W. Doerrler K.R. Feingold C. Grunfeld Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes Endocrinology 135 1 1994 141 147
236. W. Doerrler K.R. Feingold C. Grunfeld Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms Cytokine 6 5 1994 478 484
237. K.R. Feingold W. Doerrler C.A. Dinarello W. Fiers C. Grunfeld Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis Endocrinology 130 1 1992 10 16
238. C. Grunfeld K.R. Feingold Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense Proc Soc Exp Biol Med 200 2 1992 224 227
239. M. Berg D.L. Fraker H.R. Alexander Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes Cytokine 6 4 1994 425 432
240. M. Ryden E. Arvidsson L. Blomqvist L. Perbeck A. Dicker P. Arner Targets for TNF-alpha-induced lipolysis in human adipocytes Biochem Biophys Res Commun 318 1 2004 168 175
241. S.A. Beck M.J. Tisdale Lipid mobilising factors specifically associated with cancer cachexia Br J Cancer 63 6 1991 846 850
242. H.D. Mulligan S.A. Beck M.J. Tisdale Lipid metabolism in cancer cachexia Br J Cancer 66 1 1992 57 61
243. A. Hyltander P. Daneryd R. Sandstrom U. Korner K. Lundholm Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients Eur J Cancer 36 3 2000 330 334
244. A. Gambardella R. Tortoriello L. Pesce M.R. Tagliamonte G. Paolisso M. Varricchio Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients Metabolism 48 3 1999 291 297
245. P.S. Gullicksen W.P. Flatt R.G. Dean D.L. Hartzell C.A. Baile Energy metabolism and expression of uncoupling proteins 1, 2, and 3 after 21 days of recovery from intracerebroventricular mouse leptin in rats Physiol Behav 75 4 2002 473 482
246. R.B. Ceddia W.N. William Jr. F.B. Lima P. Flandin R. Curi J.P. Giacobino Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes Eur J Biochem 267 19 2000 5952 5958
247. D.E. Moller Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes Trends Endocrinol Metab 11 6 2000 212 217
248. A.L. Moreira E.P. Sampaio A. Zmuidzinas P. Frindt K.A. Smith G. Kaplan Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 6 1993 1675 1680
249. G. Reyes-Teran J. Sierra-Madero V. Martinez del Cerro Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double, blind, placebo-controlled clinical trial AIDS 10 1996 1501 1507
250. D. Landman A. Sarai S.S. Sathe Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study Clin Infect Dis 18 1 1994 97 99
251. S.S. Sathe A. Sarai D. Tsigler D. Nedunchezian Pentoxifylline aggravates impairment in tumor necrosis factor-alpha secretion and increases mycobacterial load in macrophages from AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection J Infect Dis 170 2 1994 484 487
252. G.F. Torelli M.M. Meguid L.L. Moldawer Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats Am J Physiol 277 3 Pt 2 1999 R850 R855
253. A. Jatoi S.R. Dakhil P.L. Nguyen A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group Cancer 110 6 2007 1396 1403
254. S.M. Marcora K.R. Chester G. Mittal A.B. Lemmey P.J. Maddison Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis Am J Clin Nutr 84 6 2006 1463 1472
255. J. McMurray I. Abdullah H.J. Dargie D. Shapiro Increased concentrations of tumour necrosis factor in ”cachectic” patients with severe chronic heart failure Br Heart J 66 5 1991 356 358
256. R.S. Vasan L.M. Sullivan R. Roubenoff Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study Circulation 107 11 2003 1486 1491
257. M. Cicoira A.P. Bolger W. Doehner High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients Cytokine 15 2 2001 80 86
258. L. Gullestad P. Aukrust T. Ueland Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure J Am Coll Cardiol 34 7 1999 2061 2067
259. D.L. Mann J.J. McMurray M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 13 2004 1594 1602
260. S.D. Anker A.J. Coats How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH Int J Cardiol 86 2-3 2002 123 130
261. Y. Noguchi T. Yoshikawa A. Matsumoto G. Svaninger J. Gelin Are cytokines possible mediators of cancer cachexia? Surg Today 26 7 1996 467 475
262. L.L. Moldawer E.M. Copeland 3rd Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options Cancer 79 9 1997 1828 1839
263. N.J. Espat E.M. Copeland L.L. Moldawer Tumor necrosis factor and cachexia: a current perspective Surg Oncol 3 5 1994 255 262
264. A.J. Staal-van den Brekel M.A. Dentener A.M. Schols W.A. Buurman E.F. Wouters Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients J Clin Oncol 13 10 1995 2600 2605
265. P. Ralph I. Nakoinz A. Sampson-Johannes IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor J Immunol 148 3 1992 808 814
266. M.A. Cassatella L. Meda S. Bonora M. Ceska G. Constantin Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide J Exp Med 178 6 1993 2207 2211
267. E. Vannier L.C. Miller C.A. Dinarello Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist Proc Natl Acad Sci U S A 89 9 1992 4076 4080
268. J.B. Allen H.L. Wong G.L. Costa M.J. Bienkowski S.M. Wahl Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis J Immunol 151 8 1993 4344 4351
269. C.R. Plata-Salaman Cytokine-induced anorexia Behavioral, cellular, and molecular mechanisms Ann N Y Acad Sci 856 1998 160 170
270. N.P. Turrin C.R. Plata-Salaman Cytokine-cytokine interactions and the brain Brain Res Bull 51 1 2000 3 9
271. F. Fujiki N. Mukaida K. Hirose Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer Cancer Res 57 1 1997 94 99
272. K.E. Drazan L. Wu D. Bullington A. Shaked Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse J Pediatr Surg 31 3 1996 411 414
273. G.S. Kumar U.N. Das Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins Prostaglandins Leukot Essent Fatty Acids 50 6 1994 331 334
274. E. Chyczewska R.M. Mroz Cytokines in lung cancer Rocz Akad Med Bialymst 42 Suppl 1 1997 8 22
275. E. Chyczewska R.M. Mroz E. Kowal TNF-alpha, IL-1 and IL-6 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) Rocz Akad Med Bialymst 42 Suppl 1 1997 123 135
276. N. Nishimoto J. Hashimoto N. Miyasaka Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab Ann Rheum Dis 66 9 2007 1162 1167
277. S. Busquets C. Garcia-Martinez M. Olivan E. Barreiro F.J. Lopez-Soriano J.M. Argiles Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: a role in muscle wasting? Biochim Biophys Acta 1760 2 2006 253 258
278. E. Ulfhammer P. Larsson L. Karlsson TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent J Thromb Haemost 4 8 2006 1781 1789
279. H. Fujigaki K. Saito S. Fujigaki The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines J Biochem (Tokyo) 139 4 2006 655 662
280. S. Eligini S. Stella Barbieri V. Cavalca Diversity and similarity in signaling events leading to rapid Cox-2 induction by tumor necrosis factor-alpha and phorbol ester in human endothelial cells Cardiovasc Res 65 3 2005 683 693
281. E. Hollenbach M. Neumann M. Vieth A. Roessner P. Malfertheiner M. Naumann Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease Faseb J 18 13 2004 1550 1552
282. J. Branger B. van den Blink S. Weijer Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia J Immunol 168 8 2002 4070 4077
283. S.N. Nikas A.A. Drosos SCIO-469 Scios Inc Curr Opin Investig Drugs 5 11 2004 1205 1212
284. F.S. Walsh A.J. Celeste Myostatin: a modulator of skeletal-muscle stem cells Biochem Soc Trans 33 Pt 6 2005 1513 1517
285. S.J. Lee L.A. Reed M.V. Davies Regulation of muscle growth by multiple ligands signaling through activin type II receptors Proc Natl Acad Sci U S A 102 50 2005 18117 18122
286. S.J. Lee Regulation of muscle mass by myostatin Annu Rev Cell Dev Biol 20 2004 61 86
287. T.A. Zimmers M.V. Davies L.G. Koniaris Induction of cachexia in mice by systemically administered myostatin Science 296 5572 2002 1486 1488
288. L.A. Whittemore K. Song X. Li Inhibition of myostatin in adult mice increases skeletal muscle mass and strength Biochem Biophys Res Commun 300 4 2003 965 971
289. S. Walsh E.J. Metter L. Ferrucci S.M. Roth Activin-type II receptor B (ACVR2B) and follistatin haplotype associations with muscle mass and strength in humans J Appl Physiol 102 6 2007 2142 2148
290. F. Facchinetti E. Del Giudice S. Furegato M. Passarotto A. Leon Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide Glia 41 2 2003 161 168
291. D. Osei-Hyiaman Endocannabinoid system in cancer cachexia Curr Opin Clin Nutr Metab Care 10 4 2007 443 448
292. G. Mantovani A. Maccio C. Madeddu A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress Cancer Epidemiol Biomarkers Prev 15 5 2006 1030 1034
293. S.S. Yeh S. Lovitt M.W. Schuster Pharmacological treatment of geriatric cachexia: evidence and safety in perspective J Am Med Dir Assoc 8 6 2007 363 377
294. M.D. DeBoer X.X. Zhu P. Levasseur Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia Endocrinology 148 6 2007 3004 3012
295. A. Inui A. Asakawa C.Y. Bowers Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ Faseb J 18 3 2004 439 456
296. A. Inui Ghrelin-neuropeptide Y axis in the control of feeding and gastrointestinal motility [in Japanese] Nippon Yakurigaku Zasshi 127 2 2006 83 87
297. P. Villa P. Bigini T. Mennini Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis J Exp Med 198 6 2003 971 975
298. G. Grasso A. Sfacteria A. Cerami M. Brines Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 10 2 2004 93 98
299. M. Brines A. Cerami Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise Kidney Int 70 2 2006 246 250
300. P. Villa J. van Beek A.K. Larsen Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives J Cereb Blood Flow Metab 27 3 2007 552 563
301. G. Gramignano M.R. Lusso C. Madeddu Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy Nutrition 22 2 2006 136 145
302. S. Bhasin O.M. Calof T.W. Storer Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging Nat Clin Pract Endocrinol Metab 2 3 2006 146 159
303. S.M. Roth S. Walsh Myostatin: a therapeutic target for skeletal muscle wasting Curr Opin Clin Nutr Metab Care 7 3 2004 259 263
304. E. van de Vosse M.A. van Agtmael Targets of anticytokine therapy and the risk of infections in humans and mice Curr Opin Rheumatol 19 6 2007 626 635
305. R. Doffinger S. Patel D.S. Kumararatne Human immunodeficiencies that predispose to intracellular bacterial infections Curr Opin Rheumatol 17 4 2005 440 446
306. W.J. Sandborn New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease Rev Gastroenterol Disord 5 1 2005 10 18
307. A.W. van Rijthoven J.A. van Roon Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb [in Dutch] Ned Tijdschr Geneeskd 151 14 2007 839 author reply
308. A.P. Spillane Y. Xia P.J. Sniezek Drug-induced lupus erythematosus in a patient treated with adalumimab J Am Acad Dermatol 56 5 Suppl 2007 S114 S116
309. M. De Bandt Lessons for lupus from tumour necrosis factor blockade Lupus 15 11 2006 762 767
310. K. Chatzantoni A. Mouzaki Anti-TNF-alpha antibody therapies in autoimmune diseases Curr Top Med Chem 6 16 2006 1707 1714
311. B. Kolarz B. Targonska-Stepniak D. Darmochwal-Kolarz M. Majdan Autoimmune aspects of treatment with TNF-alpha inhibitors [in Polish] Postepy Hig Med Dosw (Online) 61 2007 478 484
312. M.G. Tektonidou Neurological complications of infliximab J Rheumatol 34 1 2007 237 author reply -8
313. J.P. Stubgen Tumor necrosis factor-alpha antagonists and neuropathy Muscle Nerve 37 3 2007 281 292
314. I. Simsek H. Erdem S. Pay G. Sobaci A. Dinc Optic neuritis occurring with anti-tumour necrosis factor alpha therapy Ann Rheum Dis 66 9 2007 1255 1258
315. J. Lin D. Ziring S. Desai TNFalpha blockade in human diseases: An overview of efficacy and safety Clin Immunol 126 1 2008 13 30 Jan
316. O.M. Jolobe Anti-TNFalpha treatment and reactivation of latent tuberculosis Lancet 370 9581 2007 27 28
317. J. van Ingen M. Boeree M. Janssen Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy Nat Clin Pract Rheumatol 3 7 2007 414 419
318. J. Keane S. Gershon R.P. Wise Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 15 2001 1098 1104
319. J.E. Gottenberg F. Merle-Vincent F. Bentaberry Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy Arthritis Rheum 48 7 2003 2019 2024
320. S.L. Brown M.H. Greene S.K. Gershon E.T. Edwards M.M. Braun Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 12 2002 3151 3158
321. A. Fonollosa A. Segura J. Giralt J. Garcia-Arumi Tuberculous uveitis after treatment with etanercept Graefes Arch Clin Exp Ophthalmol 245 9 2007 1397 1399
322. J.H. Stone M.L. Uhlfelder D.B. Hellmann S. Crook N.M. Bedocs G.S. Hoffman Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety Arthritis Rheum 44 5 2001 1149 1154
323. C.T. Chou The clinical application of etanercept in Chinese patients with rheumatic diseases Mod Rheumatol 16 4 2006 206 213
324. R.A. Hansen G. Gartlehner G.E. Powell R.S. Sandler Serious adverse events with infliximab: analysis of spontaneously reported adverse events Clin Gastroenterol Hepatol 5 6 2007 729 735
325. S.M. Behnam S.E. Behnam J.Y. Koo TNF-alpha inhibitors and congestive heart failure Skinmed 4 6 2005 363 368
326. T. Bongartz A.J. Sutton M.J. Sweeting I. Buchan E.L. Matteson V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials Jama 295 19 2006 2275 2285
327. S. Acharyya D.C. Guttridge Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome Clin Cancer Res 13 5 2007 1356 1361
328. H. Wang E. Hertlein N. Bakkar NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes Mol Cell Biol 27 12 2007 4374 4387